ISO 10993-17 TRA: When Chemistry Changes the Biological Evaluation

Where Teams Go Wrong

The common failure is treating TRA as a final report that sits beside the BER. A useful TRA should change the biological evaluation. It should help decide whether a chemistry finding supports a waiver, triggers additional toxicological discussion, narrows testing, or exposes a gap in the finished-device argument.

What the TRA Should Connect

• Chemical characterization: what was detected, how confidently it was identified, and how uncertainty was handled.
• Exposure assumptions: how the detected amount relates to patient exposure and the device's contact profile.
• Toxicological thresholds: whether relevant limits, margins, or toxicological rationales support tolerability.
• Endpoint conclusions: whether the BER can support cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity, or other endpoint decisions.
• Residual uncertainty: whether more testing, better chemistry, or a clearer rationale is still needed.

How to Audit the Chemistry-to-BER Chain

A useful internal audit starts with one detected constituent and follows it all the way through the file. The question is not only whether the compound appears in the chemistry report. The question is whether the file explains what the compound means for patient exposure, toxicological concern, endpoint conclusions, and residual biological risk.

• Start with the test article: confirm that the chemistry sample represents the finished device, including processing, cleaning, packaging, and sterilization where relevant.
• Check compound handling: verify how identified, tentatively identified, and unknown compounds were treated in the toxicological assessment.
• Follow the exposure logic: make sure assumptions are visible enough for a reviewer to understand the margin or rationale being used.
• Compare against endpoint decisions: look for places where TRA conclusions should support, limit, or change the BER endpoint table.

What a Reviewer Should Be Able to Follow

The reviewer should not need to reconstruct the toxicological logic from disconnected appendices. A strong file makes the path clear: device configuration, extraction design, chemistry findings, exposure estimate, toxicological interpretation, endpoint conclusion, and final biological evaluation position. If that path is easy to follow, the TRA supports the BER. If the path is scattered, even technically useful chemistry can become a review burden.

What to Fix Before Ordering More Work

When a chemistry-driven file feels weak, the first question should be whether the existing evidence has been used properly. More chemistry, more testing, or a longer BER may still be needed, but those actions should come after the team understands the current break point.

• If the test article is unclear, fix device representation before expanding the toxicology discussion.
• If exposure assumptions are hidden, make them explicit before changing endpoint conclusions.
• If the TRA is sound but disconnected, rewrite the BER endpoint logic so the chemistry interpretation is visible.
• If uncertainty remains material, decide whether the answer is better identification, additional toxicological rationale, targeted testing, or a limited conclusion.

When Chemistry Should Change the BER

• When a constituent is detected at a level that needs toxicological interpretation.
• When an unknown or tentatively identified compound makes a waiver hard to defend.
• When the chemistry supports a lower-risk conclusion that reduces unnecessary testing.
• When a material, supplier, process, sterilization, or packaging change affects the chemical profile.
• When a reviewer asks why chemistry data was not used in the biological evaluation conclusion.

Best Next Step

For an existing file, start by mapping chemistry findings to endpoint conclusions. If the chain is broken between ISO 10993-18 data, TRA assumptions, and BER statements, fix that chain before expanding the file with more narrative or unnecessary testing.